Skip to content

A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)

A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030058
Enrollment
Unknown
Registered
2020-02-22
Start date
2020-03-10
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group :Oral leflunomide
Control group:Oral placebo

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-70 years male or female; 2. 2019 new coronavirus nucleic acid test positive; 3. meet the national diagnosis criteria; 4. subjects onset within 8 days (severe cases can be delayed to 14 days); 5. subjects or agency personnel agree to sign the informed consent; 6. subjects who can take oral medication or who receive oral medication; 7. subjects agree to collect clinical samples; 8. female subjects of child-bearing age are not pregnant and agree to take effective contraceptive measures within 7 days of the last oral medication to ensure that they will not pregnant; 9. men agree not to have sex with women for seven days after taking their last oral medication.

Exclusion criteria

Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or absorbing in oral medication; 2. pregnant and nursing women; 3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral drugs in the week prior to admission; 4. subjects exist respiratory failure requiring mechanical ventilation; 5. subjects of shock; 6. subjects combined with other organ failure requires intensive care unit; 7. subjects with no clinical expectation of survival and only give end-of-life care, or those in a deep coma who did not respond to supportive treatment within three hours of admission.

Design outcomes

Primary

MeasureTime frame
The days from positive to negative for viral nucleic acid testing;

Secondary

MeasureTime frame
Rate of progress to severe illness;Duration of fever;C reactive protein concentration in peripheral blood;Absolute value and percentage of lymphocytes in peripheral blood;Time of pulmonary imaging remission;

Countries

China

Contacts

Public ContactKe Hu

Renmin Hospital of Wuhan University

hukejx@163.com+86 18971035988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026